ArticleLa Radiologia medica2016
Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer: long-term outcome and predictor of survival.
Article in La Radiologia medica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Concurrent Bronchial Artery and Posterior Inferior Cerebellar Artery Microcatheter Interventional Chemotherapy for Adenocarcinoma of the Lung with Solitary Cerebellar Metastasis.Medical science monitor : international medical journal of experimental and clinical research · 2019Trial
- Bronchial artery infusion of PD-1 inhibitors plus chemotherapy improves progression-free survival in advanced NSCLC: a prospective cohort study.Scientific reports · 2026Article
- Iodine-125 seeds insertion with trans-arterial chemical infusion for advanced lung cancer: a meta-analysis.Journal of contemporary brachytherapy · 2022Review
- Transarterial Treatment of Lung Cancer.Life (Basel, Switzerland) · 2022Article
- Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study.Frontiers in oncology · 2022Article
- Clinical outcomes of vinorelbine loading CalliSpheres beads in the treatment of previously treated advanced lung cancer with progressive refractory obstructive atelectasis.Frontiers in bioengineering and biotechnology · 2022Article
- Successful eight-year survival of unresectable lung adenocarcinoma with bronchial artery infusion chemotherapy: A case report.Journal of interventional medicine · 2021Article
- Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer.Frontiers in cell and developmental biology · 2021Article
- Achievable complete remission of advanced non-small-cell lung cancer: Case report and review of the literature.World journal of clinical cases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the long-term outcome and the predictor of survival in patients treated with transcatheter arterial chemical infusion for advanced non-small-cell lung cancer (NSCLC). MATERIALS AND
methodsFrom May 2008 to August 2014, a total of 40 consecutive patients with advanced NSCLC who underwent transcatheter arterial chemical infusion were enrolled in this retrospective study. Data on patients' characteristics, treatment response and follow-up were collected and analyzed.
resultsA total of 142 cycles of transcatheter arterial chemical infusion were administered to the 40 patients (3.55 cycles per case). In 21 patients, only the bronchial artery was the tumor feeding artery, while in the remaining 19 patients, other arteries in addition to the bronchial artery served as the tumor feeding arteries. Five patients underwent bronchial arterial embolization after transcatheter arterial chemical infusion. There was no serious procedure-related complication. During 1-60 months (mean 11.5 ± 10.0 months) follow-up, 33 patients died. The objective response and disease control rates were 32.5 and 92.5 %, respectively. The mean time to tumor progression and overall survival was 9.2 ± 1.4 and 13.1 ± 2.0 months, respectively. Based on univariate and multivariate analyses, the independent predictors of decreasing overall survival were airway, esophagus, or superior vena cava involvement (P = 0.037) and more tumor feeding arteries in addition to the bronchial artery (P = 0.003).
conclusionTranscatheter arterial chemical infusion is an easy and effective method for treating patients with advanced NSCLC and it can provide a favorable long-term outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.